Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Celsentri

CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 37

HOS-118507 · Präparat HOS-094825

NNRTI + PI Efavirenz 600 mg QD + Maraviroc AUC12: ↑ 2.53 CELSENTRI dose should be lopinavir/ritonavir Maraviroc Cmax: ↑ 1.25 decreased to 150 mg twice 400mg/100 mg BID Efavirenz, lopinavir/ritonavir daily when co-administered (maraviroc 300 mg BID) concentrations not measured, no with efavirenz and a PI effect expected. (except tipranavir/ritonavir Efavirenz 600 mg QD + Maraviroc AUC12: ↑ 5.00 where the dose should be 600 saquinavir/ritonavir Maraviroc Cmax: ↑ 2.26 mg twice daily). 1000 mg/100 mg BID Efavirenz, saquinavir/ritonavir Concomitant use of (maraviroc 100 mg BID) concentrations not measured, no CELSENTRI and effect expected. fosamprenavir/ritonavir is not Efavirenz and Not studied. Based on the extent of recommended. atazanavir/ritonavir or inhibition by atazanavir/ritonavir or darunavir/ritonavir darunavir/ritonavir in the absence of efavirenz, an increased exposure is expected. Etravirine and Maraviroc AUC12: ↑ 3.10 CELSENTRI dose should be darunavir/ritonavir Maraviroc Cmax: ↑ 1.77 decreased to 150 mg twice (maraviroc 150 mg BID) daily when co-administered Etravirine AUC12: ↔ 1.00 with etravirine and a PI. Etravirine Cmax: ↔ 1.08 Concomitant use of Etravirine C12: ↓ 0.81 CELSENTRI and fosamprenavir/ritonavir is not Darunavir AUC12: ↓ 0.86 recommended. Darunavir Cmax: ↔ 0.96 Darunavir C12: ↓ 0.77

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) etravirine (HOS-088088) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)